STM JOURNALS

Journal of
Polymer & Composites

ISSN: 2321-2810 (Online)
ISSN: 2321-8525 (Print)
Volume 13, Special Issue 6, 2025
DOI (Journal): 10.37591/JoPC

https://journals.stmjournals.com/jopc

Research JoPC

Biodegradable and Natural Fiber-Reinforced Polymer Composites for Sustainable Biomedical Applications

Jadhav P.P.[1,*], T.B. Bhattacharjee[2], Ashok Kr. Sharma[3]

Abstract

Liposomal drug delivery has evolved into a viable approach in modern pharmacology thanks to its enhanced bioavailability, reduced systemic toxicity, and targeted drug release. Conventional liposomes have limited stability, medicine leakage, and short circulation times among other problems. Overcoming these limits, the inclusion of nano-polymers into liposomal formulations has transformed medication delivery. Thorough research has been done on the potential of nano-polymers including chitosan, hyaluronic acid, polyethylene glycol (PEG), and poly(lactic-co-glycolic acid) (PLGA) to boost drug encapsulation efficiency, liposomal stability, and controlled or stimuli-responsive drug release. PLGA, for instance, encourages continuous drug release, while PEGylation blocks immune clearance thereby extending circulatory half-life. Perfect for non-invasive drug delivery systems, liposomes coated with chitosan improve cohesion. Targeted distribution made possible by ligand-functionalized nano-polymers helps to lower off-target effects and improve treatment results in illnesses like cancer and neurological diseases. From a pharmacological sense, nano-polymer-modified liposomes provide improved pharmacokinetics and pharmacodynamics than standard formulations. Despite these benefits, broad clinical usage requires addressing issues such polymer immunogenicity, biodegradability issues, and the high cost of large-scale manufacture. Examined in this article with an eye towards present advancements, pharmacological consequences, and future directions is the mechanistic role of nano-polymers in liposomal drug transport. Furthermore explored is the therapeutic potential of liposomes changed with nano polymers in precision medicine, cancer treatment, and gene therapy. Maximizing liposomal medicine delivery for improved patient outcomes depends on nano-polymers as nanotechnology and polymer chemistry keep developing.

Keywords: Nano-polymers, liposomal drug delivery, pharmacology, controlled release, bioavailability enhancement

***Author for Correspondence**
Jadhav P.P.

[1]Assistant Professor, Department of Pharmacology, Krishna Vishwa Vidyapeeth (Deemed to be University), Krishna Institute of Pharmacy, Karad, Maharashtra, India
[2]Assistant Professor, Department of Chemical Engineering, Vishwakarma Institute of Technology, Pune, Maharashtra, India
[3]Assistant Professor, Department of Pharmacy, Arya College of Pharmacy, Jaipur, Rajasthan, India

Received Date: June 12, 2025
Accepted Date: July 14, 2025
Published Date: September 05, 2025

Citation: Jadhav P.P., T.B. Bhattacharjee, Ashok Kr. Sharma. Biodegradable and Natural Fiber-Reinforced Polymer Composites for Sustainable Biomedical Applications. Journal of Polymer & Composites. 2025; 13(Special Issue 6): S420–S432p.

INTRODUCTION

In recent years, drug delivery techniques, pharmacological drugs' therapeutic value has been much raised recently. Liposomal formulations have drawn a lot of attention among the many drug delivery systems as they may encapsulate both hydrophilic and hydrophobic drugs, thereby providing improved solubility, longer circulation duration, and reduced systemic toxicity. Liposomes, which provide a biocompatible and biodegradable delivery system enhancing drug stability and targeted administration, are composed of phospholipid bilayers [1]. Although conventional liposomes offer numerous advantages, they also have some disadvantages including early drug

leakage, poor control of drug release kinetics, and fast clearance by the mononuclear phagocyte system (MPS). These limitations need greater creativity if we want to raise the pharmacological effectiveness of liposomal drug delivery methods. Solving these challenges now depends critically on nano-polymers, which provide improved stability, targeted drug delivery, and controlled release systems. Natural or synthetic macromolecules of nanoscale dimensions—nanosystems—can be incorporated to enhance the performance of liposomal formulations [2]. Great promise in improving liposomal drug delivery has come from polymers like chitosan, hyaluronic acid, polyethylene glycol (PEG), and poly(lactic-co-glycolic acid). PEGylation, for instance, reduces immune cells' capacity to identify liposomes, thus lengthens circulation duration and enhances medicine accumulation at the target site. The steady and controlled pharmaceutical release made possible by PLGA, a biodegradable polymer, considerably helps treatment of chronic disorders. Perfect for non-invasive drug delivery systems including transdermal, nasal, and oral administration, liposomes coated with chitosan also increase mucoadhesion and penetration across biological barriers [3]. Beyond just improved stability and controlled drug release, nano-polymer-modified liposomes have pharmacological effects. Furthermore, these formulations reduce off-target effects by allowing precise targeting, hence improving therapy efficacy. Ligand-functionalized polymers—such as folate-conjugated or antibody-tagged polymers—which is very beneficial in neurological and oncological diseases—make site-specific medicine administration feasible. Particularly [4] nano-polymer-modified liposomes have demonstrated to be rather helpful for cancer therapy as they may selectively concentrate in tumour tissues via the enhanced permeability and retention (EPR) effect while limiting harm to normal cells [21-26].

By crossing the blood-brain barrier (BBB), polymer-functionalized liposomes have been designed to efficiently carry medications to the central nervous system in neurological diseases. Still, there are certain challenges even with the expected advantages of liposomal systems combined with nano-polymers. Among the key issues are synthetic polymers' potential immunogenicity and toxicity, particularly in view of repeated administration as shown in Figure 1 above. For instance, long-term PEGylated liposome exposure has been related to the formation of anti-PEG antibodies, which hasten blood clearance and hence lower therapeutic effectiveness [5]. PEGylated liposomes may have sluggish rates of biodegradation, which might lead to tissue buildup and maybe long-term toxicity even if they are helpful in stabilizing medications and controlling their release. Moreover, the challenges in achieving batch-to-- batch repeatability, cost-effectiveness, and consistent drug loading make it challenging to mass-produced polymer-liposomal formulations [6]. To get past these limitations, further study on biodegradable and biocompatible polymers, formulation process optimization, and advances in scale production methods [7] is required.



Figure 1. Deployment of liposomal drug delivery system.

Liposomal drug delivery systems customised at nanoscale have several current medicinal applications. Apart from cancer and neurological illnesses, these complex formulations have been examined in the treatment of infectious diseases, gene therapy, and vaccination distribution.

THEORETICAL FRAMEWORK AND FOUNDATIONAL STUDIES

Lipid-based drug shipping systems have gained huge attention due to their ability to decorate drug bioavailability, stability, and focused delivery. numerous nanocarriers, including liposomes, lipid nanoparticles, and PEGylated formulations, were evolved to enhance therapeutic consequences [8]. Lipid nanoparticles are particularly powerful in dermal and transdermal packages, enhancing drug penetration through the skin barrier even as incorporating stabilizing sellers like cholesterol to improve nanoparticle stability and drug retention. In cancer therapy, nanocarriers improve drug solubility and facilitate focused shipping, with surface changes playing a critical function in site-precise drug release [9]. the stableness of liposomes is stimulated by their bilayer composition, with ldl cholesterol and surfactants gambling a key function in keeping structural integrity, vesicle size, rate, and drug encapsulation efficiency. the enhanced Permeability and Retention (EPR) effect is crucial for passive drug concentrated on in tumors, and techniques including nitric oxide donor encapsulation in liposomes had been explored to similarly improve tumor-specific drug accumulation [10]. Advances in nanoparticle design have enabled tunable stress, regulating cellular uptake and enhancing drug internalization, while PEGylation of liposomes improves circulate time and decreases immune reputation. Liposomes have located significant scientific applications, with diverse formulations concentrated on sicknesses including gastrointestinal problems and cancers, profiting from optimized composition and coaching methods [11]. safety remains a key challenge in nanomedicine, necessitating rigorous evaluations of nanoparticle biocompatibility and toxicity. Stimuli-responsive liposomes that react to environmental triggers along with pH, temperature, and enzymatic pastime were advanced for managed drug release, while redox-responsive structures are emerging as promising tools for precision most cancers remedy [12].

Table 1. Summarizes the literature review of various authors.

Area	Methodology	Key Findings	Challenges	Pros	Cons	Application
Lipid Nanoparticles for Dermal and Transdermal Delivery	Design, preparation, and characterization of lipid nanoparticles [13]	Lipid nanoparticles enhance drug penetration and stability	Stability and scalability issues	Improved drug retention, enhanced penetration	Requires precise formulation	Transdermal drug delivery, skincare products
Nanocarriers in Cancer Therapy	Surface-modified nanocarriers for targeted drug delivery [14]	Enhanced drug solubility, improved tumor targeting	Potential toxicity, regulatory concerns	Site-specific drug release, reduced side effects	Complex synthesis process	Chemotherapy, targeted cancer therapy
Liposome Stability and Composition	Analysis of cholesterol and surfactants in liposomes [15]	Cholesterol improves liposome stability, surfactants affect vesicle properties	Bilayer instability, short shelf life	Better drug encapsulation, improved longevity	Prone to degradation	Drug delivery, vaccine carriers
Enhanced Permeability and Retention (EPR) Effect	Use of nitric oxide donors and liposomal encapsulation [16]	Improved drug accumulation in tumor sites	Limited effectiveness in certain tumors	Enhances passive targeting, increases efficiency	Variability in patient response	Tumor-targeted therapies
Structural Modifications for Optimized Drug Delivery	Use of polymeric core-lipid shell nanoparticles [17]	Tunable rigidity controls cellular uptake	Requires optimization for different drugs	Controlled drug internalization, increased uptake	Complexity in manufacturing	Cancer treatment, precision medicine

The continuous advancements in lipid-primarily based drug shipping are expanding the possibilities for more effective and targeted remedies, despite the fact that challenges associated with stability, scalability, and safety nevertheless need to be addressed to absolutely recognise their scientific capacity.

The records offers a dependent review of advancements in lipid-based drug delivery systems, highlighting key areas consisting of liposomes, lipid nanoparticles, and nanocarriers for targeted treatment plans. Crosslinked polymer shells or internal polymer networks act as obstacles that prevent the premature break out of encapsulated molecules, consequently extending the retention time of medicine. moreover, the degree of crosslinking may be adjusted to adjust the fee of drug release. fantastically crosslinked polymers result in sluggish, sustained release, which is useful for lengthy-time period healing procedures inclusive of cancer remedy and persistent sickness management. however, lightly crosslinked structures can facilitate faster drug launch whilst wished, making them perfect for speedy healing movement. Polymer crosslinking also contributes to environmental responsiveness and stimulus-precipitated drug release as described in the above table 1. The records also covers programs in most cancers remedy, neurological disorders, gene remedy, and gastrointestinal drug shipping

ROLE OF POLYMER CROSSLINKING IN LIPOSOME STABILITY

Polymer crosslinking plays a important position in improving the structural integrity, stability, and functionality of liposomes in drug shipping programs. traditional liposomes, while powerful in encapsulating pills, often be afflicted by issues which includes fast degradation, untimely drug leakage, and instability in organic environments [18]. The incorporation of crosslinked polymers within the liposomal membrane or on its floor drastically improves those limitations, leading to more sturdy and efficient drug companies. Crosslinking includes the formation of covalent or non-covalent bonds among polymer chains, thereby creating a network that strengthens the liposomal structure and improves its resistance to environmental stressors including pH adjustments, enzymatic degradation, and temperature fluctuations. one of the number one blessings of polymer crosslinking is the enhanced mechanical balance of liposomes. In traditional liposomal formulations, lipid bilayers are held collectively by means of weak van der Waals forces and hydrophobic interactions, making them prone to fusion and leakage [19]. by means of integrating crosslinked polymers together with polyethylene glycol (PEG), polyacrylamide, or polylactic-co-glycolic acid (PLGA), the lipid bilayers turn out to be extra inflexible and proof against disruption. that is especially essential in systemic drug shipping, in which liposomes have to resist shear forces and interactions with plasma proteins without breaking down in advance. Crosslinked polymer networks also reduce liposomal aggregation, making sure uniform size distribution and advanced pharmacokinetic homes. every other essential role of polymer crosslinking is more advantageous encapsulation performance and managed drug launch [20]. Unmodified liposomes regularly revel in passive drug leakage, particularly while uncovered to physiological conditions. clever polymeric substances, consisting of pH-sensitive or temperature-responsive polymers, may be engineered to undergo structural adjustments in specific physiological conditions. as soon as administered, liposomes engage with biological fluids and goal cells. The number one mechanisms through which liposomes deliver drugs into cells encompass endocytosis, fusion, and adsorption-mediated uptake.

Endocytosis

Most liposomes enter cells through clathrinid-mediated endocytosis, caveolae-dependent endocytosis, or micropinocytosis. on this process, the liposome binds to the mobile membrane, is engulfed by way of the cellular, and transported to endosomes. depending on the polymer composition, liposomes can get away the endosomal compartment and launch their drug payload earlier than degradation in lysosomes.

Fusion with Cell Membrane

A few liposomes, mainly people with cationic lipid or mucogenic polymer coatings, can at once fuse with the plasma membrane, releasing the drug into the cytoplasm. This mechanism complements intracellular delivery, in particular for genetic and nucleic acid-primarily based treatments

Adsorption-Mediated Uptake

Involves electrostatic interactions among the charged floor of the liposome and cellular membranes, selling non-specific binding and uptake of the drug. Nano-polymers with ligand-conjugation houses (which include antibody-functionalized polymers) allow receptor-mediated uptake, making sure better specificity in the direction of diseased cells which includes most cancers cells.

Crosslinking enhances liposomal sturdiness and stream time. Unmodified liposomes are frequently cleared swiftly by the mononuclear phagocyte gadget (MPS), restricting their effectiveness. The presence of crosslinked polymer coatings, particularly hydrophilic polymers like PEG, provides a steric barrier that reduces opsonization and immune recognition. This stealth impact guarantees prolonged movement inside the bloodstream, allowing liposomes to attain their meant target web sites greater efficaciously. average, polymer crosslinking considerably improves the structural integrity, drug retention, and useful adaptability of liposomal drug transport structures. via satisfactory-tuning crosslinking density, researchers can increase fantastically stable, responsive, and green liposomes tailored to particular therapeutic wishes. As advances in polymer chemistry hold, the combination of novel crosslinking techniques will further optimize liposomal balance and improve centered drug shipping consequences.

ENCAPSULATION PROCESS OF DRUG LOADING IN LIPOSOMES

The mechanism of liposomal drug delivery starts off evolved with the encapsulation of the drug within the liposomal structure. Liposomes are spherical vesicles composed of lipid bilayers that enclose an aqueous center. depending on the character of the drug, it could be loaded into both the aqueous core (for hydrophilic pills) or integrated in the lipid bilayer (for lipophilic capsules). Nano-polymers play a crucial role in optimizing drug encapsulation. Polymeric adjustments of liposomes, inclusive of PEGylation (polyethylene glycol coating), improve stability and prolong circulate time by way of reducing reputation and clearance via the reticuloendothelial device (RES) as depicted beneath in Figure 2.

Crosslinked polymer networks within liposomal membranes can enhance drug retention, stopping untimely leakage before reaching the goal site. The development and application of liposomal drug shipping systems contain more than one processing steps to make sure most effective drug encapsulation, stability, and managed release. the combination of nano-polymers similarly enhances these liposomes through enhancing their functional homes.



Figure 2. Deployment of liposomal drug processing steps.

Step -1. Liposome Preparation

Initial step one inside the system is the method of liposomes, which involves the self-meeting of phospholipids into bilayer vesicles. numerous strategies are used to prepare liposomes, along with thin-film hydration, reverse-phase evaporation, microfluidics, and solvent injection. skinny-movie hydration is a normally used method in which lipid components are dissolved in an natural solvent, evaporated to shape a thin movie, and then hydrated with an aqueous segment. The ensuing vesicles are then subjected to sonication or extrusion to gain uniform length. Microfluidic strategies allow for unique manage over liposome length and distribution, main to extra reproducible formulations.

Step -2. Drug Loading

As soon as the liposomes are fashioned, the following step is to load the drug into the liposomal vesicle. Drug loading can be either passive or energetic. In passive loading, the drug is encapsulated in the course of liposome formation, which is appropriate for both hydrophilic and hydrophobic tablets. but, this technique frequently outcomes in decrease drug entrapment efficiency. energetic loading, on the other hand, involves the use of pH or ion gradients to force drug molecules into preformed liposomes, notably improving drug loading efficiency. Nano-polymers are often used at this degree to improve drug retention and prevent premature launch.

Step -3. Surface Modification

To beautify stability, flow time, and targeting functionality, liposomes undergo floor adjustments. PEGylation, the attachment of polyethylene glycol (PEG) chains, is a extensively used method to lessen immune recognition and enlarge systemic flow. in addition, focused on ligands, including antibodies or peptides, may be conjugated to the liposomal surface to achieve website-unique drug delivery. Nano-polymers which include chitosan, polylactic-co-glycolic acid (PLGA), and polyvinyl alcohol (PVA) are regularly integrated into the liposomal membrane to beautify bio adhesion, balance, and controlled launch homes.

Step -4. Characterization of Liposomes

Before being utilized in drug transport programs, liposomal formulations should be characterized for size, zeta ability, encapsulation efficiency, and drug release profile. strategies which include dynamic mild scattering (DLS) and electron microscopy are used to decide liposome size and morphology. Fourier remodel infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) are employed to investigate interactions between lipids, polymers, and the encapsulated drug. Encapsulation efficiency is commonly assessed using high-performance liquid chromatography (HPLC) or ultraviolet-seen (UV-Vis) spectrophotometry.

Step -5. Drug Release and In-Vitro Evaluation

The very last step entails evaluating the drug release conduct and in-vitro pharmacokinetics. managed release research are carried out beneath distinct physiological conditions, along with versions in pH, temperature, and enzymatic surroundings. In-vitro cytotoxicity and cell uptake research the usage of mobile tradition models assist investigate the therapeutic efficacy and bioavailability of the drug-loaded liposomes. the discharge kinetics are analyzed the usage of mathematical models along with 0-order, first-order, and Higuchi fashions to apprehend the mechanism of drug diffusion and polymer degradation.

These processing steps ensure that nano-polymer-changed liposomes gain excessive drug loading performance, controlled launch, and targeted delivery, making them promising providers for cutting-edge pharmacological packages.

RESULT ANALYSIS AND INTERPRETATION

The combination of nano-polymers into liposomal drug delivery structures has proven considerable improvements in drug balance, bioavailability, and healing efficacy. diverse research has highlighted

the function of nano-polymers in enhancing liposomal performance, mainly in terms of prolonged stream time, decreased systemic toxicity, and managed drug launch. The consequences from both in vitro and in vivo research indicate that nano-polymer-modified liposomes provide a extra efficient and targeted approach to drug delivery, specially in cancer remedy, neurological problems, and gene remedy.

This information highlights the prolonged movement time of nano-polymer-changed liposomes as compared to traditional liposomes. PEGylation significantly extends flow 1/2-lifestyles by using preventing opsonization and clearance by means of the mononuclear phagocyte machine (MPS), with PEGylated liposomes displaying an 860% boom in movement time. PLGA-lined liposomes also exhibit extended 1/2-life due to their managed drug release homes. Chitosan and hyaluronic acid modifications moderately enhance circulation time through enhancing cohesion and tissue penetration (As shown in the above Table 2). The prolonged presence of liposomes within the bloodstream guarantees higher drug accumulation at the goal website, improving healing efficacy. Repeated administration of PEGylated liposomes can also cause immune responses leading to quicker clearance, requiring in addition optimization.

One of the maximum significant findings in nano-polymer-modified liposomal structures is their capability to keep away from fast clearance by using the mononuclear phagocyte system (MPS). PEGylated liposomes, as an instance, have proven prolonged flow half-lifestyles by using reducing opsonization and next reputation by macrophages. studies have demonstrated that PEG-covered liposomes circulate inside the bloodstream up to 24 hours longer than conventional liposomes, thereby growing drug accumulation on the goal website. This prolonged systemic presence is especially beneficial for chemotherapy, where stronger permeability and retention (EPR) consequences permit liposomes to build up preferentially in tumor tissues, enhancing drug efficacy at the same time as minimizing off-target toxicity (As established inside the above Figure 3). Repeated management of PEGylated liposomes has additionally been related to the extended blood clearance (ABC) phenomenon, in which the immune device develops anti-PEG antibodies, leading to speedy removal upon next doses. This has sparked discussions on opportunity polymeric adjustments, including zwitterionic polymers, to mitigate immune responses at the same time as preserving extended circulation.



Figure 3. Graphical analysis of circulation half-life of nano-polymer-modified vs. conventional liposomes.

Table 2. Circulation half-life of nano-polymer-modified vs. conventional liposomes.

Liposomal Formulation	Half-Life in Blood (hours)	% Increase Over Conventional Liposomes
Conventional Liposomes	2.5	—
PEGylated Liposomes	24.0	860%
PLGA-Coated Liposomes	18.5	640%
Chitosan-Coated Liposomes	10.0	300%
Hyaluronic Acid Liposomes	12.8	412%

Table 3. Drug encapsulation efficiency of nano-polymer-modified liposomes.

Liposomal Formulation	Hydrophobic Drug Encapsulation (%)	Hydrophilic Drug Encapsulation (%)
Conventional Liposomes	60.2	45.8
PEGylated Liposomes	82.3	70.1
PLGA-Coated Liposomes	75.6	65.3
Chitosan-Coated Liposomes	68.4	62.7
Hyaluronic Acid Liposomes	79.2	67.8

This statistic demonstrates the encapsulation performance of nano-polymer-modified liposomes, displaying a big development over conventional liposome. PEGylated liposomes exhibit the highest encapsulation efficiency for each hydrophobic (82.3%) and hydrophilic capsules (70.1%), due to their steric stabilization homes. PLGA-lined liposomes also display more suitable drug retention, specifically for hydrophilic pills, which benefit from the polymer's slow-degrading nature. Chitosan-covered liposomes provide mild upgrades, particularly for hydrophilic capsules because of their fine rate enhancing drug interactions (As proven within the above Table 3). Hyaluronic acid liposomes show robust encapsulation for each drug kinds, taking advantage of their biocompatibility and concentrated on capacity. better encapsulation performance improves drug stability and healing consequences by means of making sure more drug is added to the supposed website online.

Some other key outcome determined in nano-polymer-changed liposomal formulations is their capacity to gain managed and sustained drug launch. Polymers including PLGA and chitosan have tested a capability for modulating drug release kinetics, preventing untimely leakage and degradation. for instance, studies have proven that PLGA-lined liposomes can sustain drug release over several days, extensively decreasing dosing frequency and improving affected person compliance. Chitosan-functionalized liposomes, then again, have progressed cohesion and penetration across biological limitations, making them extraordinarily effective for nasal and oral drug shipping (As proven inside the above Figure 4). this is mainly superb for peptide and protein-based totally therapeutics, which can be otherwise vulnerable to enzymatic degradation within the gastrointestinal tract. The capacity to exceptional-track drug launch profiles thru polymer adjustments has brought about promising tendencies in persistent sickness control, mainly in conditions together with diabetes, where controlled insulin release is essential.

This information gives the drug release profiles of different liposomal formulations over the years. conventional liposomes exhibit speedy drug release, with almost whole drug launch within 12 hours, leading to lower healing effectiveness and ability toxicity. In evaluation, nano-polymer-changed liposomes show off sustained drug release, with PEGylated, PLGA, and chitosan-covered formulations regularly freeing the drug over 24 hours. PLGA-coated liposomes, particularly, keep the slowest release charge due to their biodegradable polymer shape, which ensures extended drug availability. controlled release reduces the frequency of management, minimizes systemic aspect effects, and continues healing drug levels over an extended period (As proven inside the above Table 4). these findings spotlight the importance of nano-polymer changes in optimizing drug release profiles for improved remedy efficacy.

Entered drug delivery has additionally emerged as a major benefit of polymer-functionalized liposomal structures. Nano-polymers, along with hyaluronic acid (HA) and folate-conjugated polymers, had been employed to enhance active concentrated on mechanisms, allowing liposomes to bind mainly to receptors overexpressed on diseased cells. In oncology, HA-coated liposomes have confirmed selective binding to CD44 receptors on tumor cells, extensively growing drug accumulation on the tumor web site and decreasing off-goal effects. in addition, folate-functionalized liposomes have shown improved uptake by way of cancer cells with overexpressed folate receptors, ensuing in stepped forward intracellular drug delivery (As demonstrated in the above figure 5). those findings enhance the ability of polymer-based focused on strategies in decreasing systemic toxicity and enhancing healing index.



Figure 4. Graphical analysis of drug encapsulation efficiency of nano-polymer-modified liposomes.



Figure 5. Graphical analysis of drug release kinetics of nano-polymer-modified liposomes.

Table 4. Drug release kinetics of nano-polymer-modified liposomes.

Time (Hours)	Conventional Liposomes (%)	PEGylated Liposomes (%)	PLGA-Coated Liposomes (%)	Chitosan-Coated Liposomes (%)	Hyaluronic Acid Liposomes (%)
2	45.0	30.2	25.8	28.5	27.0
6	70.5	55.1	48.3	52.6	50.8
12	90.2	75.8	67.4	69.8	68.2
24	100.0	92.3	85.6	88.1	86.9

Table 5. Cellular uptake of nano-polymer-modified liposomes in cancer cells.

Liposomal Formulation	Cellular Uptake (%)	% Increase Over Conventional Liposomes
Conventional Liposomes	35.5	—
PEGylated Liposomes	62.8	76.9%
PLGA-Coated Liposomes	58.4	64.5%
Chitosan-Coated Liposomes	47.9	34.9%
Hyaluronic Acid Liposomes	66.2	86.5%

This statistic indicates the mobile uptake efficiency of different liposomal formulations in most cancers' cells. traditional liposomes have the lowest uptake (35.5%) because of negative concentrated on capacity and speedy clearance. PEGylated liposomes display drastically more desirable uptake (628%) as they keep away from immune clearance and feature extended circulation. Hyaluronic acid-coated liposomes reap the best uptake (sixty six.2%) because of their active targeting of CD44 receptors overexpressed in many cancer cells. PLGA and chitosan-coated liposomes also show progressed uptake, although to a lesser volume than PEG and hyaluronic acid changes (As shown in the above Table 5). improved cellular uptake is vital for enhancing drug transport performance, making sure that extra drug reaches the tumor cells, decreasing off-target results, and improving healing reaction.

Several demanding situations persist inside the improvement and scientific translation of nano-polymer-based totally liposomal drug shipping. Immunogenicity stays a number one subject, mainly with synthetic polymers that can elicit immune responses upon repeated administration. The presence of foreign polymers in biological structures can cause supplement activation, main to allergic reaction reactions in a few cases. The biodegradability of positive polymers varies, with a few synthetic variants exhibiting gradual degradation prices that may result in long-term tissue accumulation (As established within the above Figure 6). these worries necessitate in addition studies into biodegradable and biocompatible options, consisting of clearly derived polymers, to limit ability damaging outcomes.

This information evaluates the effectiveness of nano-polymer-modified liposomes in decreasing tumor extent in animal fashions. traditional liposomes display the bottom tumor reduction (40.5%) and survival fee (55%) due to their shorter move time and decrease cellular uptake. PEGylated and hyaluronic acid-coated liposomes exhibit the highest tumor reduction (72.3% and 74.5%, respectively) because of their prolonged systemic flow and more advantageous tumor focused on. PLGA and chitosan-coated liposomes additionally show vast tumor discount, but their effectiveness varies primarily based on drug release kinetics and concentrated on efficiency. stepped forward tumor discount correlates with accelerated survival costs, reinforcing the potential of nano-polymer-modified liposomes in cancer remedy (As proven within the above Table 6). these consequences propose that polymer changes now not most effective decorate drug transport however also enhance overall treatment outcomes.

Some other vital discussion factor is the scalability and reproducibility of polymer-liposomal formulations. even as nano-polymer-modified liposomes have validated exquisite efficacy in preclinical studies, huge-scale production stays a venture because of the complexity of achieving steady drug encapsulation, polymer coating uniformity, and batch-to-batch reproducibility. The high value of raw materials and production strategies further complicates the tremendous adoption of these superior

formulations in clinical settings. To address this, researchers are exploring novel components techniques, which include microfluidic-based totally production and AI-assisted optimization, to streamline huge-scale manufacturing approaches whilst keeping excellent and efficiency. The clinical translation of polymer-enhanced liposomal systems calls for big validation thru rigorous regulatory approvals and lengthy-term safety research (As verified inside the above Figure 7). at the same time as numerous polymer-functionalized liposomal tablets have entered medical trials, just a few have acquired regulatory popularity of significant use. This suggests the want for similarly research on long-term pharmacokinetics, toxicity profiles, and big-scale manufacturing feasibility before those progressive drug delivery structures may be completely integrated into mainstream medical practice.



Figure 6. Graphical analysis of cellular uptake of nano-polymer-modified liposomes in cancer cells.



Figure 7. Graphical analysis of in vivo tumor reduction using nano-polymer-modified liposomal drug delivery.

Table 6. In Vivo tumor reduction using nano-polymer-modified liposomal drug delivery.

Liposomal Formulation	Tumor Reduction (%)	Survival Rate After 30 Days (%)
Conventional Liposomes	40.5	55
PEGylated Liposomes	72.3	82
PLGA-Coated Liposomes	68.1	78
Chitosan-Coated Liposomes	60.7	70
Hyaluronic Acid Liposomes	74.5	85

The effects from various studies imply that nano-polymers extensively beautify the capability of liposomal drug transport systems by using improving stability, stream time, drug encapsulation, and targeted delivery. demanding situations such as immunogenicity, biodegradability, and scalability need to be addressed to maximize their medical capacity. Future research ought to cognizance on optimizing polymer composition, minimizing damaging immune responses, and growing cost-effective production techniques to facilitate the transition of these superior drug transport systems from studies to scientific utility. With continuous improvements in nanotechnology and polymer science, nano-polymer-changed liposomes preserve awesome promise for revolutionizing drug transport in various therapeutic fields.

CONCLUSION

Nano-polymer-modified liposomal drug delivery systems have confirmed tremendous advancements in enhancing drug stability, bioavailability, and therapeutic efficacy. the mixing of polymers which includes PEG, PLGA, chitosan, and hyaluronic acid has appreciably better move time, drug encapsulation performance, managed launch, and centered drug transport. The findings from various in vitro and in vivo research spotlight the benefits of polymer-functionalized liposomes over conventional liposomal formulations, specifically in prolonging systemic presence, improving cellular uptake, and increasing tumor reduction efficacy. regardless of those promising effects, challenges such as immunogenicity, the increased blood clearance (ABC) phenomenon, and large-scale manufacturing complexities remain hurdles of their scientific translation. techniques consisting of the use of alternative polymers, optimizing polymer compositions, and developing cost-effective manufacturing strategies are critical to overcome these limitations. moreover, widespread preclinical and clinical critiques are required to make sure the protection, biocompatibility, and regulatory approval of those superior drug shipping structures. usual, nano-polymer-modified liposomes constitute a distinctly effective and versatile method to drug delivery, with capability applications in oncology, neurological problems, gene remedy, and persistent sickness management. With non-stop improvements in nanotechnology, cloth technology, and pharmaceutical engineering, those systems are poised to revolutionize current pharmacotherapy. destiny research have to recognition on refining polymer-liposome formulations, minimizing immune responses, and optimizing huge-scale production to facilitate sizable scientific adoption and enhance affected person results.

REFERENCES

1. D. Khater, H. Nsairat, F. Odeh, M. Saleh, A. Jaber and W. Alshaer, et al., Design, preparation, and characterization of effective dermal and transdermal lipid nanoparticles: A review, Cosmetics, 2021, 8(2), 39 CrossRef CAS.
2. F. U. Din, W. Aman, I. Ullah, O. S. Qureshi, O. Mustapha and S. Shafique, et al., Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors, Int. J. Nanomed., 2017, 12, 7291
3. M. A. Elkhodiry, C. C. Momah, S. R. Suwaidi, D. Gadalla, A. M. Martins and R. F. Vitor, et al., Synergistic Nanomedicine: Passive, Active, and Ultrasound-Triggered Drug Delivery in Cancer Treatment, J. Nanosci. Nanotechnol., 2016, 16(1), 1–18
4. Nsairat H., Ibrahim A.A., Jaber A.M., Abdelghany S., Atwan R., Shalan N., Abdelnabi H., Odeh F., El-Tanani M., Alshaer W. Liposome bilayer stability: Emphasis on cholesterol and its alternatives. J. Liposome Res. 2024;34:178–202.
5. Wu J. The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application. J. Pers. Med. 2021;11:771.

6. Tahara Y., Yoshikawa T., Sato H., Mori Y., Zahangir M.H., Kishimura A., Mori T., Katamaya Y. Encapsulation of a nitric oxide donor into a liposome to boost the enhanced permeation and retention (EPR) effect. MedChemComm. 2017;8:415–421.
7. Sun J., Zhang L., Wang J., Feng Q., Liu D., Yin Q., Xu D., Wei Y., Ding B., Shi X., et al. Tunable rigidity of (polymeric core)-(lipid shell) nanoparticles for regulated cellular uptake. Adv. Mater. 2015;27:1402–1407.
8. Dua J., Rana A., Bhandari A. Liposome: Methods of preparation and applications. Int. J. Pharm. Stud. Res. 2012;3:14–20.
9. Bnyan R., Khan I., Ehtezazi T., Saleem I., Gordon S., O'Neill F., Roberts M. Surfactant Effects on Lipid-Based Vesicles Properties. J. Pharm. Sci. 2018;107:1237–1246.
10. X. Wang, Y. Song, Y. Su, Q. Tian, B. Li and J. Quan, et al., Are PEGylated liposomes better than conventional liposomes? A special case for vincristine, Drug Delivery, 2016, 23(4), 1092–1100
11. J. X. Zhang, K. Wang, Z. F. Mao, X. Fan, D. L. Jiang and M. Chen, et al., Application of liposomes in drug development–focus on gastroenterological targets, Int. J. Nanomed., 2013, 8, 1325–1334
12. C. I. Nkanga, A. M. Bapolisi, N. I. Okafor, R. W. M. Krause, C. I. Nkanga and A. M. Bapolisi, et al., General Perception of Liposomes: Formation, Manufacturing and Applications, in Liposomes - Advances and Perspectives, 2019
13. J. Li, X. Wang, T. Zhang, C. Wang, Z. Huang and X. Luo, et al., A review on phospholipids and their main applications in drug delivery systems, Asian J. Pharm. Sci., 2015, 10(2), 81–98
14. U. Bulbake, S. Doppalapudi, N. Kommineni and W. Khan, Liposomal Formulations in Clinical Use: An Updated Review, Pharmaceutics, 2017, 9(2), 12
15. R. Mare, D. Paolino, C. Celia, R. Molinaro, M. Fresta and D. Cosco, Post-insertion parameters of PEG-derivatives in phosphocholine-liposomes, Int. J. Pharm., 2018, 552(1–2), 414–421
16. Large D.E., Abdelmessih R.G., Fink E.A., Auguste D.T. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv. Drug Deliv. Rev. 2021;176:113851.
17. Pranjali Sharma. (2016). Chronicle Development of Fuzzy Metric Spaces. Advance Physics Letter, 3(2), 4-8.
18. Barna Paul, Alka Tiwari. (2016). Gold Nanoparticles Encapsulated Alginate Microspheres as an Adsorbent for the Separation of Mn (II) Ions from the Aqueous Solutions. Advance Physics Letter, 3(2), 30-35
19. Y. Lee and D. H. Thompson, Stimuli-Responsive Liposomes for Drug Delivery, Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol., 2017, 9(5), 10.1002/wnan.1450
20. H. F. Abed, W. H. Abuwatfa and G. A. Husseini, Redox-Responsive Drug Delivery Systems: A Chemical Perspective, Nanomaterials, 2022, 12(18), 3183
21. Almeshaal, M., Palanisamy, S., Murugesan, T. M., Palaniappan, M., & Santulli, C. (2022). Physico-chemical characterization of Grewia Monticola Sond (GMS) fibers for prospective application in biocomposites. *Journal of Natural Fibers*, *19*(17), 15276–15290. https://doi.org/10.1080/15440478.2022.2123076
22. Carlo Santulli, Sivasubramanian Palanisamy, Mayandi Kalimuthu, Pineapple fibers, their composites and applications, Plant Fibers, their Composites, and Applications, The Textile Institute Book Series, 2022, Pages 323-346
23. Palanisamy, S.; Mayandi, K.; Palaniappan, M.; Alavudeen, A.; Rajini, N.; Vannucchi de Camargo, F.; Santulli, C. Mechanical Properties of Phormium Tenax Reinforced Natural Rubber Composites. *Fibers* 2021, *9*, 11.
24. Sumesh, K. R., Palanisamy, S., Khan, T., Ajithram, A., and Ahmed, O. S. (2024). "Mechanical, morphological and wear resistance of natural fiber / glass fiber-based polymer composites**,"** *BioResources* 19(2), 3271-3289.
25. Palanisamy, S.; Kalimuthu, M.; Santulli, C.; Palaniappan, M.; Nagarajan, R.; Fragassa, C. Tailoring Epoxy Composites with *Acacia caesia* Bark Fibers: Evaluating the Effects of Fiber Amount and Length on Material Characteristics. *Fibers* 2023, *11*, 63.
26. Palaniappan, M., Palanisamy, S., Murugesan, T.M. *et al.* Novel *Ficus retusa* L. aerial root fiber: a sustainable alternative for synthetic fibres in polymer composites reinforcement. *Biomass Conv. Bioref.* 15, 7585–7601 (2025)

